Guideline-concordant therapy and outcomes in healthcare-associated pneumonia.
about
Healthcare-Associated Pneumonia Does Not Accurately Identify Potentially Resistant Pathogens: A Systematic Review and Meta-AnalysisImpact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.Update in respiratory infections 2011.Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community StudyA comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international studyStaphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department.Bacteriological assessment of healthcare-associated pneumonia using a clone library analysisAssociation of guideline-based antimicrobial therapy and outcomes in healthcare-associated pneumonia.Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia.Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia.Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatmentMicrobiology of healthcare-associated infections and the definition accuracy to predict infection by potentially drug resistant pathogens: a systematic review.Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010.The effect of statin therapy on the incidence of infections: a retrospective cohort analysis.Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score.Guideline-concordant antimicrobial therapy for healthcare-associated pneumonia: a systematic review and meta-analysis.Current treatment of community-acquired pneumonia.Healthcare-associated pneumonia: a US disease or relevant to the Asia Pacific, too?Introduction to propensity scores.Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy.Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes.Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia.Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia.Clinical and microbiological features of patients admitted to the intensive care unit with nursing and healthcare-associated pneumonia.Community-acquired pneumonia versus healthcare-associated pneumonia. The returning pendulum.Treatment Trends and Outcomes in Healthcare-Associated Pneumonia.Isolation of ESBL-producing Bacteria from Sputum in Community-acquired Pneumonia or Healthcare-associated Pneumonia Does Not Indicate the Need for Antibiotics with Activity against This Class.Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy.Reply to Livorsi and Eckerle.Why do nonsurvivors from community-acquired pneumonia not receive ventilatory support?
P2860
Q29543747-A9F17141-11C5-4951-A707-FFC7CB3BBD99Q33572569-799FD9CA-CE68-40B9-ADC1-724BCE65AE77Q33738738-BF2BAAA1-80B7-4106-A165-CC09DAEE91F4Q33904263-AACD500D-423F-4AC2-9A15-DA1D8D8E2631Q34464399-77A7D318-CF93-4813-B741-3DF204CB5AA5Q34478074-58234D13-92B5-4BCD-BE42-5A8B59DACBE9Q35086947-467133D5-6AE5-4B92-82C0-5AF253320AB8Q35432136-9C2C2607-12CA-422B-8E53-6976039BA4ABQ35432641-C6B73E34-4174-48F0-A360-20FB63C53177Q35732814-555C2A54-4B78-411C-94BD-0AEAA47F5D9FQ35780121-21F1CC8E-4914-4BFE-BF7D-5FE7366DAB0CQ35780916-B815969A-DB8E-4D1F-BCC6-6452290A4180Q35865273-5E5FC85C-7664-408E-B572-95BD892D9553Q36141276-69916A64-78CC-46EE-971F-D59EFAF590ADQ36876210-6C004185-0088-4A1A-B197-C3F9C5E9987FQ36888089-9EA042C4-5968-4C49-85A9-2E7564C2C090Q38097737-F2E26789-44F6-4046-BE71-1918F2C8822AQ38105639-F7E0CC21-010D-4203-996B-6A65B5554C05Q38109968-73C26125-3DB8-44AD-98F3-E0FDACA6FE16Q38217008-0511354D-870E-418F-AE6E-3A8B9F897983Q39051283-73912C36-482F-4A6E-AC61-3BCC224FBF9FQ39422204-2FEB8BD3-F087-4E2D-B93F-B3DC17E23393Q40196287-1851C6D3-A6A6-4121-BBD1-3257557CD82AQ41428636-F4C433E0-B21C-4032-9803-161CC5442AC8Q41560626-810940F4-A9C0-4D56-A56E-79D9A5196142Q43974180-6E0080B9-7294-4004-8700-2E01C1EF6589Q47726442-3D1F4E87-FFD5-418F-B2C4-C0D654A606FFQ47747140-6E3F3B9F-451F-499B-9349-FD9E275391BAQ48538620-23B8E3EC-0B3A-43EC-BCA4-16463472E1EBQ51168038-835716C4-386F-4A13-B78C-2A8522BDADD8Q51724809-B3181A3E-95B5-489B-9344-F9390B83E0FAQ52884063-6A9A26FB-506E-4739-B2C0-4760B475F716
P2860
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia.
@en
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia.
@nl
type
label
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia.
@en
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia.
@nl
prefLabel
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia.
@en
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia.
@nl
P2093
P1476
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia
@en
P2093
P304
P356
10.1183/09031936.00141110
P577
2011-03-24T00:00:00Z